Samuraciclib
Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib has anti-tumor effects[1][2].
Product Specifications
CAS Number
1805833-75-3
Product Name Alternative
CT7001; ICEC0942
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Apoptosis; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/samuraciclib.html
Purity
99.55
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O[C@H]1CNCC[C@@H]1CNC2=NC3=C(C(C)C)C=NN3C(NCC4=CC=CC=C4)=C2
Molecular Formula
C22H30N6O
Molecular Weight
394.51
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9
Citation 01
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
EN2, CT (Homeobox Protein Engrailed-2, Homeobox Protein en-2, Hu-En-2) (MaxLight 650) discontinued
